Submission of the unaudited financial results for Quarter and half year ended, 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals has reported its Q2 FY26 and H1 FY26 results, approved by the Board on November 14, 2025. Revenue from operations for H1 FY26 stood at Rs. 492.74 lakhs, up roughly 74% year-on-year from Rs. 283.72 lakhs in H1 FY25. The company returned to profit with a Profit After Tax (PAT) of Rs. 48.77 lakhs for H1 FY26, compared to a loss of Rs. 22.64 lakhs in the same period last year, translating to EPS of Rs. 1.06 versus a negative Rs. 0.49 earlier. Operating cash flow turned healthy at Rs. 63.06 lakhs (vs a marginal Rs. 1.61 lakhs a year ago). However, finance costs rose to Rs. 36.99 lakhs and current borrowings remain at Rs. 903.74 lakhs against equity of Rs. 531.64 lakhs, indicating an elevated debt burden. The statutory auditor (Pulindra Patel & Co.) issued a clean limited review report with no qualifications.
A clear turnaround story — sharp revenue growth and a swing to profit alongside improving cash flows are positive signals for shareholders. However, the high debt-to-equity (around 1.7x) and rising interest costs are concerns that could weigh on the stock despite the earnings recovery.